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Preeclampsia (PE) is a common disorder of pregnancy originating in the placenta.We exam-
ined whether excessive activation or poor regulation of the complement system at the
maternal–fetal interface could contribute to the development of PE. Location and occur-
rence of complement components and regulators in placentae were analyzed. Cryostat
sections of placentae were processed from 7 early-onset PE (diagnosis<34 weeks of ges-
tation), 5 late-onset PE, 10 control pregnancies, and immunostained for 6 complement
activators and 6 inhibitors. Fluorescence was quantified and compared between PE and
control placentae. Gene copy numbers of complement components C4A and C4B were
assessed by a quantitative PCR method. Maternal C4 deficiencies (≥1 missing or non-
functional C4) were most common in the early-onset PE group (71%), and more frequent
in late-onset PE compared to healthy controls (60 vs. 38%). Complement C1q deposi-
tion differed significantly between control and patient groups: controls and early-onset PE
patients had more C1q than late-onset PE patients (mean p=0.01 and p=0.005, respec-
tively). C3 activation was analyzed by staining for C3b/iC3b and C3d. C3d was mostly
specific to the basal syncytium and C3b/iC3b diffuse in other structures, but there were no
clear differences between the study groups. Activated C4 and membrane-bound regulators
CD55, CD46, and CD59 were observed abundantly in the syncytiotrophoblast. Syncytial
knots, structures enriched in PE, stained specifically for the classical pathway inhibitor
C4bp, whereas the key regulator alternative pathway, factor H (FH) showed a wider dis-
tribution in the placenta. Differences in C1q deposition between late- and early-onset PE
groups may be indicative of the different etiology of PE symptoms in these patients. Irreg-
ular distribution of the complement regulators C4bp and FH in the PE placenta and a
higher frequency of C4A deficiencies suggest a disturbed balance between complement
activation and regulation in PE.
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INTRODUCTION
Preeclampsia (PE) is a serious complication of human pregnancy.
It can lead to multi-organ dysfunction and, rarely, to a life-
threatening convulsive condition, eclampsia (1). PE affects 3–5%
of pregnancies in all ethnic groups. The development and pro-
gression of the disease are unpredictable. Presently, delivery of the
placenta remains the only cure for PE. The etiology of PE is still
largely unknown. Because of the unique challenge that the fetopla-
cental unit poses to the maternal immune system PE could involve
a non-classical-type incompatibility (2).
The complement (C) system is a phylogenetically ancient
means of self–non-self discrimination. It plays a central role
in innate immune defense, clearance, and as a mediator of the
adaptive immunity (3). Complement activation is regulated by
soluble and membrane-bound inhibitor molecules. Activation
of the C system releases potent anaphylatoxins, which generate
inflammation by mediating chemotaxis, increased vascular per-
meability, smooth muscle contraction, and leukocyte activation.
In addition, C has been indicated in the homeostatic clearance of
waste products as well as in regenerative processes. The discrimi-
nation potential of C goes beyond that between self and non-self,
because C can distinguish non-viable tissue components and cells
from viable ones. In particular, a disturbed binding of the soluble
regulator factor H (FH) to injured or altered host cells could allow
an alternative pathway-mediated attack against such target. Also,
exposed subcellular or disturbed membrane structures could initi-
ate both classical and alternative pathway activation, either directly
or via activating molecules like C-reactive protein (CRP) or natural
antibodies.
Disturbances in C activity can predispose to infections or to a
systemic lupus erythematosus (SLE)-like immunoinflammatory
syndrome. The latter has been related to an inadequate waste
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disposal function of the classical pathway (4). These types of syn-
dromes tend to become worse during pregnancy, possibly because
of a greater challenge to the clearance system posed by material
derived from the placenta. On the other hand, disturbances in
C regulation can lead to such catastrophic consequences as the
atypical hemolytic uremic syndrome (aHUS) and other forms of
thrombotic microangiopathy (TMA) (5). Central to these is C
attack against endogenous tissue structures, endothelial cells, and
blood cells that can lead to vascular damage and organ failure,
notably in kidneys. Pregnancy is a well-known potential trigger
for such syndromes.
The depth of placentation required for a healthy human preg-
nancy presents a unique challenge to regulation of the maternal
immunological processes (6, 7). For the trophoblast invasion and
healthy placentation to occur, the fetal cells must avoid recognition
by and activation of the C system (7). A risk for the latter exists
because of the potential development of maternal antibodies or
spontaneous activation of the C system by exposed villous struc-
tures, which are often observed in the PE placentae by microscopy.
A well regulated C system is a prerequisite for a healthy preg-
nancy (8, 9). Recently, mutations in C regulatory genes have been
reported in women with recurrent pregnancy loss (10). Recently, a
case report was published, where treatment with the C5 inhibitor
eculizumab prolonged HELLP (hemolysis, elevated liver enzymes,
and low platelets)/PE pregnancy by 17 days. The treatment resulted
in a clinical improvement of the patient and normalization of her
lab parameters supporting the role of C in the pathogenesis of
PE (11). Up to our knowledge, however, the C system has never
been described in its entirety in the PE placentae in comparison
with healthy control placentae. In particular, little information is
available on the possible role or dysfunction of the two major solu-
ble inhibitors FH and C4b binding protein (C4bp) in the placenta
during pregnancy.
Two forms of C4 exist, C4A and C4B, which are the targets for
control by the C4bp regulator protein. Genes for C4A, C4B, as well
as for C2 and factor B, are encoded in the MHC class III region in
the human chromosome 6p21.3. C4 genes are polymorphic, vari-
ations in gene copy numbers exist and deficiencies are common
(12). Deficiencies in C2 and C4A predispose to SLE, a disorder
known to worsen during pregnancy (13, 14). Because of the vascu-
lar disturbance in PE and its similarity to many diseases involving
C dysfunction (SLE, phospholipid antibody syndrome, aHUS) we
found it reasonable to hypothesize that an imbalance between C
activation and regulation could be involved in PE (Figure 1).
To test the involvement of C in PE, we have analyzed immuno-
histochemically the deposition and expression of key activat-
ing components and regulators of the C system in preeclamp-
tic placentae in relation to disease onset and in comparison to
healthy placentae. The results favor the hypothesis that an insuf-
ficient complement function is linked to an inability to clear
away trophoblast material from the placenta. As a consequence,
the material deposits in fibrinoid clusters and could cause an
endothelial–vascular disorder in the maternal circulation.
MATERIALS AND METHODS
PATIENTS
For this study, we chose randomly 12 women with PE and 10
controls without PE (Table 1) from the prospective arm of the
Finnish Genetics of Preeclampsia Consortium (FINNPEC) cohort.
While FINNPEC is a multicenter study, all women in this study
FIGURE 1 | A model of innate immunity incompatibility between
maternal and fetal cells in preeclampsia and the maternal immune
system. Failure of complement regulation on fetal tissue or excessive
activation of the maternal complement system could result in complement
attack against 1) invading trophoblast cells or 2) placental syncytiotrophoblast
that represent the discordant interfaces. Accordingly, an imbalance between
complement activation and regulation could contribute to the pathogenesis of
preeclampsia. Specific foci for complement to attach could include syncytial
bodies (apoptotic syncytial knots and syncytial sprouts), which are observed
more often in preeclamptic placentae than in healthy controls.
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Table 1 | Clinical characteristics of the study population.
Controls Late-onset Early-onset
N =10 PE, n=5 PE, n=7
Age 30.6±3.1 33.8±4.1 31±6.5
Gravidity 1.8±0.8 1.2±0.5 1.9±1.1
Parity 0.6±0.8 0.2±0.5 0.6±1.0
Maternal BMI (kg/m2) 22.9±2.7 21.0±2.2 22.3±2.4
Hypertension before
pregnancy
1/10 1/5 2/7
Celiac disease 0/10 1/5 0/0
Thrombophilia 0/10 0/5 1/7
PE in previous pregnancy 0/10 1/5 1/7
Early pregnancy systolic
BP (mmHg)
114±8 117±7 129±10b,c
Early pregnancy diastolic
BP (mmHg)
73±8 77±5 82±9a
Highest systolic BP
(mmHg)
128±13 166±10b 167±16b
Highest diastolic BP
(mmHg)
87±10 109±8b 118±9b
Highest proteinuria (g/24 h) – 1.8±0.4 5.7±3.8b,c
Gestational weeks at birth 40±2 38±2a 33±4b,c
Birth weight (g) 3646±282 2938±423b 1842±544b,d
Complications
IUGR – – 3/7
Placental insufficiency – – 2/7
HELLP – 1/5 1/5
aSignificant in <0.05 level when compared with controls.
bSignificant in <0.01 level when compared with controls.
cSignificant in <0.05 level when compared with late-onset group.
dSignificant in <0.01 level when compared with late-onset group.
Mean ± SD values are shown.
PE, preeclampsia; BMI, body mass index; BP, blood pressure; IUGR, intrauterine
growth restriction; HELLP, hemolysis; elevated liver enzymes, low platelets.
delivered at the Helsinki University Central Hospital. Placental
samples (nine-site biopsies) were collected after delivery from the
patients. All pregnancies were singletons and exclusion criteria
were multiple pregnancies or maternal age <18 years. An addi-
tional exclusion criterion was a known autoimmune disease such
as SLE. All subjects provided a written informed consent and the
FINNPEC study protocol was approved by the coordinating Ethics
Committee of the Hospital District of Helsinki and Uusimaa.
Preeclampsia was defined as hypertension and new-onset pro-
teinuria occurring after 20 weeks of gestation. Hypertension was
defined as systolic blood pressure of 140 mmHg or more, and/or
a diastolic blood pressure of 90 mmHg or more after 20 weeks
of gestation. Proteinuria was defined as the urinary excretion of
≥0.3 g protein in a 24-h specimen, or 0.3 g/l or, in the absence
of concurrent quantitative measurement, at least a “2+” or more,
or two “1+” proteinuria dipstick readings with no evidence of
urinary tract infection. PE was considered severe if blood pres-
sure was ≥160/110 mmHg, or proteinuria exceeded 5 g/24 h, or
symptoms like cerebral or visual disturbances or abdominal pain
appeared. Intrauterine growth restriction (IUGR)/placental insuf-
ficiency was defined as birth weight below−2SD and/or umbilical
artery resistance≥+2SD according to gestational age specific stan-
dards (15) without known etiology unrelated to the aims of the
present project (e.g., congenital malformation syndromes and
chromosomal defects). We have divided the PE women into two
groups according to the weeks of gestation at diagnosis: early-onset
<34 weeks of gestation (n= 7), late-onset ≥34 weeks of gestation
(n= 5).
Placental samples were chosen preferentially from patients with
severe and early-onset PE. Chronic hypertension (an elevated
blood pressure that predated the pregnancy or detected before
mid-pregnancy) was observed in three PE women and one woman
in the control group (Table 1). Two women had HELLP syndrome.
One woman of the late-onset PE group had celiac disease and one
patient of the early-onset PE group had thrombophilia caused by
mutation in the coagulation factor FII.
SAMPLE PREPARATION
Approximately 1 cm wide tissue samples from the placentae were
dissected using a scalpel and scissors and placed in a cryotube for
preservation. Following the nine-site procedure, the placenta was
visually divided into nine pre-specified regions and one sample was
taken from each region. Within 2 h of the delivery of the placenta,
the cryotubes containing samples were placed into the inner com-
partment of a nested metal holder. Approximately 150 ml of liquid
nitrogen was added to the outer compartment to cool down the
150 ml isopropanol poured into the inner compartment. Accord-
ing to a standardized tissue-preserving collection procedure, the
samples were left for 20 min to freeze slowly through the iso-
propanol pool. When isopropanol reached a floury frozen state,
the cryotubes were stored at −80°C. For our study, one region
(no. 5) was immunohistochemically analyzed from all samples.
ANTIBODIES AGAINST COMPLEMENT FACTORS
The antibodies used are listed in Table 2. Primary antibodies were
chosen to detect either the activating components or regulators of
the alternative and classical pathways of complement activation.
Soluble endoglin (s-eng) was used as a positive control for changes
in PE placenta (16).
Anti-C3c antibody was used to detect C3b and iC3b, which are
the products of alternative pathway activation and amplification
and of subsequent C3b inactivation. C3d fragment was separately
stained for because the C3d antibody recognizes the C3dg frag-
ment, which remains surface bound after the release of C3c. FH
binds to the C3b molecule on the self-cell surface, where it can be
detected by the FH antibody. The C1q antibody recognizes sev-
eral different structures of the classical pathway activating C1q
molecule. The C4c antibody recognizes the native C4 molecule
www.frontiersin.org July 2014 | Volume 5 | Article 312 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lokki et al. Complement in preeclamptic placenta
Table 2 | Primary antibodies used for immunofluorescence stainings.
Antibody Type Dilution Sourcea Role
C1q Rabbit pAb 1:1000 DAKO CP component
C4c Rabbit pAb 1:400 DAKO CP component
C4bp Sheep pAb 1:200 The Binding Site CP regulator
CRP Mouse mAb 1µg/ml Fitzgerald CP activator
C3c Rabbit pAb 1:1000 DAKO AP component
C3d Rabbit pAb 1:1000 DAKO AP component
Factor H Goat pAb 1:400 Calbiochem AP regulator
C9 Goat pAb 1:400 Quidel TP component
MCP (CD46) Mouse mAb 1µg/ml IBGRL AP and CP regulator
Bric 230 (CD55) Mouse mAb 1µg/ml IBGRL AP and CP regulator
Bric 229 (CD59) Mouse mAb 1:200 IBGRL TP regulator
CR1 Mouse mAb 1µg/ml AbD Serotec AP and CP regulator
s-Endoglin Mouse mAb 2µg/ml Santa Cruz PE indicator
aDAKO, Glostrup, Denmark; The Binding Site, Birmingham, UK; Fitzgerald Industries International, North Acton, MA, USA; Calbiochem, Merck KGaA, Darmstadt,
Germany; Quidel Corporation, San Diego, CA, USA; IBGRL The International Blood Group Reference Laboratory, Bristol, UK; AbD Serotec, Oxford, UK; Santa Cruz
Biotechnology, Inc., Dallas, TX, USA.
pAb, polyclonal antibody; mAb, monoclonal antibody.
CP, classical pathway; AP, alternative pathway, TP, terminal pathway; PE, preeclampsia.
(both C4A and C4B) as well as the activation product C4b and its
inactivated form iC4b. For detection of C4bp, a cofactor for C4b
in activation, a polyclonal sheep antibody was used. Membrane-
bound DAF (CD55) and MCP (CD46) were analyzed by specific
mouse monoclonal antibodies.
IMMUNOFLUORESCENCE STAINING
The frozen tissue samples were cryosectioned at 5µm and when
possible two or three serial sections were laid per each slide. The
dried sections were rinsed with phosphate-buffered saline (PBS)
and moist samples were blocked against non-specific binding with
1% bovine serum albumin (BSA) in PBS for 15 min in a humid
chamber. Excess liquid was discarded and the first antibody was
pipetted to the sample in 1% BSA/PBS as detailed in Table 2. One
section on the slide was used for a mock staining by treating it with
only 1% BSA/PBS without the first antibody (Figures 4D,H,L;
5D,H and 6D,H,L). After washing for five times (1 min each) the
second antibody was pipetted at a 1:300 dilution in 1% BSA/PBS.
Second antibodies used were Alexa 488-labeled antibodies against
goat, rabbit, mouse, and sheep immunoglobulins (Invitrogen,
Thermo Fisher Scientific,Waltham, MA, USA). After 20-min incu-
bation and five 1-min rinses, excess liquid was removed and a
mounting medium was added. Stained sections were kept at+4°C
in the dark until documentation on the same day.
HISTOCHEMISTRY
One slide from each sample was used for standard automated
hematoxylin and eosin (HE) staining to ensure diagnostic-level
consistency and to obtain a histological reference point for the
immunofluorescence (IFL) analyses.
IMAGING AND HISTOLOGICAL ANALYSIS
Data were collected using standardized fluorescence microscopy
settings, where all slides were photographed with 10×, 20×, and
40× magnifying objectives. Exposure times per each magnifi-
cation were 20, 50, and 83.3 ms. Images were collected using
Olympus DP Manager (ver. 2.2.1.195) and Olympus DP Con-
troller (ver. 2.2.1.227) image capture softwares with Olympus
BX51 fluorescence microscope camera.
The same protocol and machinery for imaging was used for
histochemistry preparations. Images captured from HE stained
samples were used to identify key structures and to characterize the
placenta. The structures to be identified included stem villi, small
villi, villous fibrinoid (i.e., as a part of a villus, often replacing syn-
cytium), fibrinoid necrosis, syncytiotrophoblast (STB), cytotro-
phoblast, fetal arterial endothelium, and syncytial bodies (incl.
syncytial sprouts and syncytial knots). The occurrence of syncy-
tial bodies and fibrinoid structures was semiquantified by grading
(0= none observed, 1= counted 1–3, 2=>3, 3= all over, cannot
be counted). Structural integrity was measured by intactness of
syncytium and special attention was paid on shedding of syncytial
cells. Signs of nuclei of apoptotic cells were looked for and noted.
GENETIC ANALYSIS
To correlate the C4 deposition observed in the placentae with the
functional C4 genes, C4A and C4B gene copy numbers and a
silencing C4A mutation were analyzed using a previously pub-
lished protocol (12). Briefly, a SYBR® Green labeled real-time
quantitative polymerase chain reaction (qPCR) with a specified
concentration range approach was used to obtain numbers of
C4 and to detect deficiencies due to CTins, which renders the
affected C4A non-functional. Two copies of C4A and C4B are
considered the normal genotype and while deviations from the
four-gene norm are common, individuals with less than two
genes for either C4 gene or individuals with C4A CTins muta-
tion are considered C4 deficient. DNA for the qPCR protocol was
extracted from whole blood samples of mothers and from umbil-
ical cord blood samples collected post-partum from the placenta.
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Blood samples were stored in−80°C and DNA was later extracted
using Macherey-Nagel NucleoSpin Blood XL kit (Macherey-Nagel
GmbH & Co., KG Düren, Germany). Extracted DNA was stored
at−80°C until used in the analysis.
STATISTICAL ANALYSIS
ImageJ 1.46 and Fiji-win32 softwares were used to quantify the
intensity of fluorescence in the fixed magnification images. These
were chosen to minimize the variation of staining quality and tis-
sue quality between individuals, which was more apparent at the
highest levels of magnification. To correct for false positive read-
ings resulting from background autofluorescence, mean intensity
+1 SD (X¯+σ)was determined to be 7 at 20 ms exposure and 15 at
50 ms exposure. This was calculated from analysis of negative con-
trols (Figures 4D,H,L; 5D,H and 6D,H,L). Using the appropriate
zero thresholds each image was analyzed for several parameters
of fluorescence intensity. Sum was defined as mean intensity *
area of positive fluorescence in pixels (X¯ × σ). The purpose of
using different parameters was to differentiate between different
patterns as well as intensity of fluorescence. Log10 transformation
was used to normalize the image capture data and normality of
the transformed data was verified by Shapiro–Wilk W test (data
not shown). An independent-samples t -test for analyzing the sig-
nificance of differences between means of values obtained from
patient groups and controls was carried out for key statistical
parameters including sum and mean as well as the clinical mea-
surements. For the high-intensity analysis, the top 75% proportion
of fluorescence histogram was determined for each image using
ImageJ 1.46 software and the calculated maximum fluorescence
value (Figure 2). A filter was placed at the calculated 75%
minimum value creating representative images of high-intensity
regions. Statistical testing of the high-intensity area percentage
was done as above (data not shown). Furthermore, Pearson-
correlation of high-intensity proportions between different stain-
ings was calculated for each patient group independently. Positive
correlations were used as an indicator of two components observed
in the same sample, while negative correlations were interpreted as
two components occurring in different samples. Fisher’s exact test
was used to analyze for differences between segregation of C4 gene
deficiencies between groups of patients, and independent-samples
t -test was used to assess the association of C4 gene deficiencies and
immunohistochemistry fluorescence sum and mean values.
RESULTS
Activating components and regulators of the C system as well
as s-endoglin were found to be deposited in the placenta in a
structure-specific manner showing differences between patient
groups and controls. In the following, the results are presented
according to C pathways (Figure 3).
CLASSICAL PATHWAY
C1q
C1q was observed at the STB layer in 5/10 controls but in none
of the early- onset PE patients and only in one of the late-onset
FIGURE 2 | High-intensity analysis workflow of C4bp staining of an
early-onset preeclamptic placenta using ImageJ 1.46 software. The
image is processed through steps (A–D) to produce a quantification of
the high-intensity fluorescence areas, which correspond to the
structures where (C) deposition/expression is most conspicuous.
(A) The original image. (B) Black and white rendering of the image in
(A). (C) Threshold set at 75% positive fluorescence (calculated to be
value 77 for this image). (D) Area (in pixels) of positive signal (in green),
% area is given in output and compared across and between the
patient groups.
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FIGURE 3 | Summary of expression patterns of complement
components in the placenta. Our findings are highlighted in black arrows
(PE: preeclampsia, LO-PE: late-onset preeclampsia). Pictured are the
components that we studied in their respective position in the activation
cascade (green solid lines and shapes) or regulatory network (red dotted
lines and shapes). The C system is composed of approximately 20 plasma
proteins, which can be activated in a stepwise cascade via the classical (CP,
via Ag-Ig: immunocomplexes or CRP: C-reactive protein), lectin (LP), or the
alternative pathway (AP). In addition, there are approximately 15
components that act as receptors or protective molecules on cell
membranes. All three pathways result in the activation of the main
complement component C3 and thereafter of the terminal pathway causing
the formation of membrane attack complexes (MACs) and ultimately target
cell damage. C5b (not studied, in gray) is the activated component at the
onset of terminal pathway. FH is a regulator of the alternative pathway,
where its main role is to act as a cofactor for Factor I in the cleavage of C3b
into iC3b. Similarly in the classical pathway, cleavage of C4 to activated
form C4b is inhibited by a potent regulator C4bp. C3b and C4b are both
generated by activation of not only the classical, but of the lectin pathway
as well. C1q is a potent activator of the classical pathway. Binding of the
complex (C1qr2s2) activates the C4 step. Together with decay accelerating
factor (DAF; CD55) and membrane cofactor protein (MCP, CD46), C4bp
regulates the progression of the classical C pathway by controlling the
formation and function of the classical pathway C3 convertase, C4b2a. Like
FH, MCP can also act as a cofactor in C3b inactivation. In the classical
pathway, DAF accelerates the disassembly of C4b2a and in the alternative
pathway that of C3bBb. DAF is a glycosylphosphatidylinositol-anchored
membrane molecule. Complement receptor type 1(CR1, CD35) is a
membrane-bound regulator expressed primarily by bone-marrow
derived cells.
PE patients. Overall, we found less C1q in the PE patients when
compared with normal controls (Figures 4A–C). In about half of
the cases, C1q was observed in the endothelia of placental vessels.
In the ImageJ analysis, the amount of C1q deposition was higher
in controls and early-onset PE group than in late-onset PE group
(mean p= 0.01 and mean p= 0.005, respectively) (Tables 4 and
5). Accordingly, the area of high-intensity regions for C1q stain-
ing was significantly smaller in the late-onset PE cases than in
controls (p= 0.005) and in the early-onset PE group (p= 0.011).
In the areas of high-intensity staining, the tissue structure was
breaking down suggesting an on-going necrotic process. C1q was
frequently found in the stromal areas of the larger villi. Samples
with large villi containing C1q abundantly were observed more
frequently in the patients (both groups combined) vs. controls
(58 vs. 40%), especially in the early-onset PE group (71%). C1q
was present also in the fibrinoid necrotic areas especially in the
placentae of patients in the early-onset PE group. Less C1q was
seen in the fibrinoid areas of the late-onset group or normal
controls.
C4 gene numbers
C4A or C4B deficiencies were found almost twice as often in
early-onset PE patients than in healthy controls (Table 3). C4A
deficiencies were found in 40% (2/5) of PE mothers with late-onset
disease and 43% (3/7) of PE mothers with early-onset disease.
None were observed in the controls (n= 7). Because of the small
number of samples, the difference was on the borderline statisti-
cally significant (p= 0.055 Fisher’s exact two-sided test). Only two
individuals had total C4 deficiency (total C4A deficiency in one
control mother and total C4B deficiency in one child born from
early-onset PE pregnancy).
C4
C4 deposits were observed mainly in the STB layer, either in the
apical membrane or throughout the syncytium. There was no clear
difference between the patient groups and controls in this pattern
(Tables 4 and 5). A particular staining for C4 was seen in clusters
formed from the STB layer. These clusters represent syncytial bod-
ies (i.e., syncytial knots or sprouts) and shedding of the syncytium.
The number of C4 clusters was slightly higher in the preeclamp-
tics (Figures 5E–G). The intensity of the C4 fluorescence mean or
sum values did not associate with C4A or C4B deficiencies of the
mother or fetus.
C4bp
C4bp is an inhibitor of the classical pathway occurring usu-
ally physiologically in complex with the anticoagulant protein S.
Overall, C4bp was found deposited particularly in small syncytial
bodies, which appeared as brightly staining particles attached or
sometimes shed from the syncytium (see Figures 1 and 5B). Char-
acteristically, these were seen as dense clusters of bright staining,
which were interpreted as small necrotic, apoptotic, or fibrinoid
tissue fragments, typically syncytial knots (Figure 5A). In contrast
to other C regulators C4bp was not deposited in a circumferen-
tial continuum on the syncytium, while it was typically observed
only on the apical surface of the syncytium. Of the controls 80%
(8/10) showed apical C4bp staining in the STB whereas in PE
cases 42% (5/12) had some C4bp deposition on the STB layer
(Figure 5). The stromas of the villi were negative and also the
placental endothelium was mostly negative for C4bp. In a few
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FIGURE 4 | Side-by-side comparison of C1q, C9, and s-Eng staining of
the same individual placentas. C1q is absent from large villi of the
late-onset PE control. (B) There is a negative correlation between
high-intensity areas of C1q and C9. s-Endoglin is deposited on the
syncytiotrophoblast of PE placentae (I,J) and absent from the control
placenta (K). Top row (A,E,I): early-onset PE. Middle top row (B,F,J):
late-onset PE. Middle bottom row (C,G,K): control. Bottom row (D,H,L):
negative control (antibody I omitted). 20× magnification.
Table 3 | Frequency of C4A and/or C4B deficiencies in preeclamptic (PE) patients and controls.
C4A or C4B deficiency C4A deficiency C4B deficiency
Maternal Fetal Maternal Fetal Maternal Fetal
PE (pooled) (n=12) 0.667 0.700 0.417 0.300 0.333 0.400
Early-onset PE (7) 0.714 0.667 0.429 0.333 0.286 0.333
Late-onset PE (5) 0.600 0.750 0.400 0.250 0.400 0.500
Control (8) 0.375 0.500 0 0.375 0.375 0.250
placentae small necrotic/fibrin containing areas were intensely
stained for C4bp (Figure 5C). These were observed in both cases
and controls.
C-reactive protein and Complement Receptor type 1 (CR1;
CD35) were tested with four samples representing one early-onset
PE, two late-onset PE and one control specimens. Both staining
were negative. CRP and CD35 were subsequently omitted from
the protocol.
ALTERNATIVE PATHWAY
C3
In general, C3 (C3b, iC3b) detected by an antibody against C3c
was abundantly present in the placenta. It was found in the STB
layer and in the villous stroma (Figures 6A–C). In 4 out of 10 con-
trol placentae (40%) C3 reactivity was observed on the apical and
basal linings of the STB layer. In contrast, this was observed only
in one out of seven samples (14%) of the early-onset PE group.
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Table 4 | Complement and s-endoglin deposition in early- and late-onset preeclampsia (PE) vs. control.
Type of
PE onset
C3b/iC3b C1q C4bp C4
Control Control Control Control
t p df t p df t p df t p df
Sum Late 1.735 0.106 13 2.793 0.015 13 −0.487 0.635 13 0.969 0.352 12
Early −0.671 0.512 15 −0.530 0.604 15 −0.667 0.516 14 0.486 0.635 14
Mean Late 1.718 0.110 13 2.993 0.01 13 −0.374 0.714 13 0.703 0.495 12
Early −0.607 0.553 15 −0.091 0.929 15 −0.507 0.620 14 0.432 0.672 14
Type of
PE onset
FH C3d C9 s-Endoglin
Control Control Control Control
t p df t p df t p df t p df
Sum Late 0.059 0.954 13 −0.217a 0.836 5.463 0.825 0.424 13 1.842 0.090 12
Early −0.913a 0.378 12.533 −0.365a 0.723 9.333 −0.129 0.899 15 1.524 0.150 14
Mean Late 0.067 0.947 13 0.097 0.924 13 0.722 0.454 13 2.825 0.015 12
Early −0.812a 0.431 12.927 −0.009 0.993 15 −0.215 0.833 15 1.815 0.091 14
Mean fluorescence intensity and sum of intensity are compared between early- and late-onset PE and controls. C1q and soluble endoglin show significant or borderline
significant differences.
aEqual variances not assumed.
Bold significant to the 0.05 level.
Italics borderline significant.
df, degrees of freedom.
In half of all samples weak staining for C3 was also observed in
the placental endothelium, without clear differences between the
study groups.
The intensity of C3 deposition appeared weaker in the PE group
and even more so in the late-onset group when compared with
normal pregnancy (Figures 6B,C).
The samples were stained separately also for C3d because
it is the C3 activation product that remains covalently bound
in areas of C3b deposition thus reflecting a longer period of
C activation. C3d deposition was also present in the placenta
(Figures 6E–G). Reactivity was seen in the villous stroma but
a clearer pattern was observed in the syncytium. C3d reactivity
was observed mainly in the basal membrane of the syncytium
(14/22). The pattern on the syncytial basement membrane was
either partially or more fully circumferential lining of the villi
(Figure 6G). No clear difference was observed between the patient
groups and normal controls in the C3d abundance or pattern
(Tables 4 and 6).
Factor H
Factor H is a key regulator of the C amplification cascade in the
alternative pathway. There was significant variation in the FH
staining patterns in different placentae (Figures 6I–K). In the con-
trol placentae, FH localized evenly to the STB layer in 70% (7/10)
of the placentae. Often both the apical and the basal layer were
stained. Apical side of the STB layer was sometimes more strongly
or exclusively stained.
In certain PE placentae, only the STB layer of some villi and
fibrin clusters had become strongly stained for FH, while the rest
of the tissue remained negative (Figure 6K). In other samples, vil-
lus stroma was FH-positive throughout, with distinct patterns in
the fetal endothelium, STB layer, and in fibrin clusters (Figure 6I).
The basal–apical STB layer pattern observed in most controls was
only observed in a third (4/12) of the PE placentae. C1q depo-
sitions correlated negatively with the soluble regulator FH in the
late-onset group (Table 7). Calcareous and necrotic areas were
intensely stained for FH (Figure 6K).
TERMINAL PATHWAY
The terminal complex of C activation was assessed by staining
for tissue associated C9. It could represent deposited polymeric
MAC or tissue-bound SC5b-9 complexes. Positive staining for C9
was found in distinct regions of the placentae (Figures 4E–G).
A strong staining was seen in the basal membrane of the STB
layer (Figure 4G). C9 was also seen in the villous stroma in a
non-regular pattern (Figure 4E). The most abundant staining for
C9 was seen in the fibrinoid and necrotic/calcified areas. There
were no differences between the PE and control groups in the C9
staining patterns or intensities (Tables 4–6).
MEMBRANE REGULATORS
The membrane-bound regulators of complement MCP, DAF, and
CD59 were typically observed in a dual pattern, where both the
apical and the basal layer of the STB stained positive. Membrane
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FIGURE 5 | Side-by-side comparison of C4 and C4bp stainings in the
same placental samples. C4 is deposited in syncytial knots, visible as bright
clusters but also in the syncytia of selected villi. C4bp is observed in syncytial
bodies. C4bp is not observed in a circumferential pattern of the syncytium. C4
and C4bp are both observed in fibrinoid structures [here in control panels
(G,C)]. Top row (A,E): early-onset PE. Middle top row (B,F): late-onset PE.
Middle bottom row (C,G): control. Bottom row (D,H): negative control
(antibody I omitted). 20× magnification.
regulators were mainly observed in the STB layer and to a lesser
extent in the villar endothelium. DAF showed the weakest stain-
ings of the membrane regulators. Unlike the soluble regulators,
membrane-bound regulators were not observed in the syncytial
bodies (Figure 1) nor in apoptotic, necrotic, or fibrinoid struc-
tures. No differences in the expression patterns of membrane reg-
ulators were observed between PE patients and healthy controls or
between the early-onset and late-onset PE (data not shown). The
C3b/C4b receptor CR1 (CD35) was not detected in the placentae
of the control group or patients (data not shown). This indicates
the lack of leukocytes in the placenta.
s-ENDOGLIN
We found s-endoglin to be significantly more abundant in PE
pregnancies than in healthy controls (Table 6), especially in the
late-onset disease group (Tables 4 and 5).
In PE, villi in 83% (10/12) of the placentae had distinct and
circumferential endoglin deposition on the apical sides of the
STB, sometimes penetrating through to the basal layer. Villi with
negative staining in the STB were scarce (Figures 4I,J). In control
placentas, s-endoglin was found mostly in the apical side of the STB
layer. 20% of controls had a thin but circumferential deposition
pattern on the STB of the villi. While some villi displayed a
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FIGURE 6 | Side-by-side comparison of C3b/iC3b, C3d, and FH staining
patterns in the same placentas. C3b/iC3b and FH are observed in stromas
of large stem villi [early-onset preeclampsia (PE): (A,I) and control: (C)] and
in fibrinoid structures (J). C3d is typically observed in circumferential
pattern of basal membrane of the syncytium (E–G). The circumferential
pattern is often interrupted in PE (E,F) where physical damage to the
syncytium causes increased rate of syncytial shedding. Top row
(A,E,I): early-onset PE. Middle top row (B,F,J): late-onset PE. Middle bottom
row (C,G,K): control. Bottom row (D,H,L): negative control (antibody I
omitted). 20× magnification.
somewhat even positive layer, many villi stained negative or had
only a few faintly positive deposits (Figure 4K).
DISCUSSION
Differences between women with and without PE were seen in the
classical pathway of C activation and in the binding of protective
C regulators to the placental structures. The critical differences
were mostly observed at the STB layer and in lesions represent-
ing injured tissue structures. C1q deposition on the STB was least
abundant in the late-onset PE group. Interestingly, in our small
study sample we observed that C4 deficiencies were more com-
mon in women with PE compared to women without PE. C4bp
was localized to the syncytial bodies, which were more commonly
seen in PE. FH was seen in the villi around the STB, although
the extent of its binding varied greatly between individuals. In PE
patients, less FH in the STB was observed.
Abundant evidence suggests that immunological mechanisms
are involved in the various steps of PE pathogenesis. These include
an incomplete spiral artery remodeling that causes poor placental
development and creates turbulent and constrained blood flow to
the villi (17). This in turn will aggravate the physical strain on the
placental tissue and may lead to vascular symptoms typical for PE.
An abnormal C function could limit the ability of C to maintain
its waste disposal function. Accumulation of waste products in the
placenta and insufficient repair functions could be related to the
pathophysiology of PE.
The overall deposition of C1q was stronger in the early-onset
than in the late-onset PE, which may reflect the difference in
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Table 5 | Complement and s-endoglin deposition in early- vs. late-onset preeclampsia (PE).
Type of
PE onset
C3b/iC3b C1q C4bp C4
Late Late Late Late
t p df t p df t p df t p df
Sum Early 1.219 0.251 10 2.273 0.046 10 0.176 0.864 9 0.639 0.537 10
Mean Early 1.297 0.224 10 3.614 0.005 10 0.127 0.902 9 0.364 0.723 10
Type of
PE onset
FH C3d C9 s-Endoglin
Late Late Late Late
t p df t p df t p df t p df
Sum Early 0.773 0.457 10 0.074 0.943 10 0.857 0.412 10 0.588 0.569 10
Mean Early 0.722 0.487 10 0.085 0.934 10 0.810 0.437 10 0.511 0.621 10
Mean fluorescence intensity and sum of intensity are compared between early- and late-onset PE and controls. Both sum and mean of C1q differs significantly
between the two patient groups.
Bold significant to the 0.05 level.
df, degrees of freedom.
Table 6 | Complement and s-endoglin deposition in preeclampsia (PE) vs. control.
dg C3b/iC3b C1q C4bp C4
Control Control Control Control
t p df t p df t p df t p df
Sum PE −1.417 −0.172 20 −1.695 0.106 20 −0.775 0.448 19 0.848 0.407 19
Mean PE −1.366 0.187 20 −1.493 0.151 20 −0.602 0.554 19 −0.664 0.515 19
dg FH C3d C9 s-Endoglin
Control Control Control Control
t p df t p df t p df t p df
Sum PE 0.458 0.652 20 0.045 0.964 20 −0.411 0.685 20 2.008 0.059 19
Mean PE 0.407 0.689 20 −0.398a 0.695 18.961 −0.330 0.745 20 2.463 0.023 19
Pooled PE and controls compared using mean fluorescence intensity and sum of intensity as measurements. Only soluble endoglin is significantly (mean) or borderline
(sum) significantly different across the groups.
aEqual variances not assumed.
Bold significant to the 0.05 level.
Italics borderline significant.
df, degrees of freedom.
dg, diagnosis.
the etiopathogenesis between these two patient groups. Placen-
tal dysfunction is typically observed in the early-onset disease. We
observed a higher frequency of necrotic large villi and an increased
number of fibrinoid necrotic areas in the early-onset PE placentas
(2, 18, 19). Importantly, in the early-onset PE placentae, a high-
intensity area of C1q was found to lack C9, which indicates that
C1q deposition probably does not result in the activation of the
terminal pathway in these patients. If C4 deposition is consid-
ered indicative of classical pathway activation, missing C1q in the
PE patients’ syncytium, where C4 deposits were typically observed,
suggests that C1q deposition has other functions apart from classi-
cal pathway activation in the placenta. The classical pathway of the
C system is triggered e.g., by the binding of C1q to immune com-
plexes, CRP and other pentraxins or by intracellular components
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Table 7 | Correlations of high-intensity area percentage values between different components per patient group.
Component 1 Component 2 Pearson’s r p (2-Tailed)
Early-onset PE C1q C9 −0.878 0.009
DAF C4 0.824 0.023
C3b/iC3b s-Eng 0.829 0.021
Late-onset PE C1q FH −0.932 0.021
C4 C9 0.921 0.026
C4bp C4 0.962 0.009
Control DAF MCP 0.634 0.049
C4bp MCP −0.659 0.038
FH C9 0.671 0.034
Significant correlations to the 0.01 level is indicated in bold, others are significant to 0.05 level.
PE, preeclampsia.
released upon cell damage (20). The possibly elevated plasma CRP
levels of PE patients were not reflected in the placental deposition
of CRP according to our findings (21).
Our results support the theory, that C1q has an important
role in the maintenance of immune tolerance by clearing apop-
totic and self-antigens. C1q has an important ability to recognize
altered or exposed structures of self thereby leading to their effi-
cient clearance by phagocytes without lysis and inflammation (22).
Direct binding of C1q may occur to various structures, such as to
phospholipids or vimentin exposed by vascular endothelia during
tissue damage (23). Deficiency in C1q is associated with a major
insufficiency in the clearance of apoptotic cells. This causes an
SLE-like disease often involving glomerulonephritis (24). In PE, a
partially similar function for C1q could be envisioned. Continuing
stress and, by definition, the temporary existence of placenta may
predispose the STB to cellular damage.
High-intensity areas of C1q deposition were negatively corre-
lated with the soluble regulator FH in the late-onset PE group. This
could be a reflection of a C1q/FH balance. Our results suggest that
C1q could also bind to structures exposed by a turbulent blood
flow during PE. These structures could be within the connective
tissue, in vascular endothelia or on the trophoblastic cells. It was
recently shown that FH can bind independently from and even
compete with C1q for binding to apoptotic surfaces and other tar-
gets (25). When FH binds directly to the apoptotic surface and
tissue debris, it may serve to further dampen the inflammatory
response initiated via the classical pathway.
We found an increasing frequency of C4A deficiencies with
the severity of the PE diagnosis. C4A deficiencies are observed in
approximately 16% of the Finnish general population (14, 26).
We found a 2.5-fold increase in the occurrence of C4A deficiency
(40%) in the late-onset PE group and a slightly higher frequency
in the early-onset group (43%). Because of the small sample size,
the studies need to be repeated in a larger material. Based on our
interesting preliminary results such a study is underway. While
the two C4 proteins, C4A and C4B, have mainly overlapping func-
tions, some differences may also be observed (27). C4A deficiencies
are often associated with susceptibility to autoimmune diseases
(28). Our patients and controls were selected so that patients
with immunological diseases that might be associated with C4A
deficiency, such as SLE, were excluded. Low plasma C4 levels in
preeclamptic women have been previously found to be the only
abnormality in a panel of C components measured in PE pregnan-
cies and healthy controls (29). The presence of two C4 products
with differing functions could explain, why in that study, C4 levels
observed in the placenta did not associate with the known defi-
ciency status, as the used antibody does not discriminate between
the two forms of C4.
C4bp is a major soluble protein that binds to C4b and reg-
ulates the classical pathway C3 convertase. We observed C4bp
binding typically and intensely to apoptotic fragments and struc-
tures including shed and knotted syncytium. Because of this, it was
not possible to quantitatively differentiate if fluorescence intensity
levels in relation to disease status were due to the different levels
of physical damage of the placenta or to truly different levels of
C4bp (30). C4bp is known to bind directly to surfaces of apop-
totic and necrotic cells (31, 32). Furthermore, syncytial bodies
such as syncytial knots and sprouts might be more common in PE
(33). Interestingly, analyses of the high-intensity fluorescence areas
showed a strong correlation between C4bp, C4, and C9. This could
be indicative of classical pathway activation. Previous reports of
C4bp in PE are few and inconclusive. Mellembakken et al. found
no difference in C4bp plasma levels of preeclamptics and con-
trols, while Schjetlein et al. reported a decrease in C4bp plasma
levels with increasing severity of PE (29, 34). Recently, mutations
in C4bp were found to be related to recurrent pregnancy loss in
certain patients (10).
Factor H is the most important regulator of the alternative
pathway. Generally, FH was observed in abundance in most of
the placentae. The absence of STB staining for FH in the PE
cases, a trend which was also apparent with other C compo-
nents, is likely due to the loss of surface negative charge and/or
disturbed structure of the STB in the preeclamptic placentae. In
clusters of C3b deposition, e.g., in areas of STB damage, FH would
also bind. Considering that FH is a soluble molecule, it seems
atypical that in 83% of cases and 40% controls, intense FH depo-
sition was observed in the stromas of the tissue. This suggests an
increased requirement of the tissue for protection from C attack
in majority of the placentae from preeclamptic pregnancies. Inter-
estingly, FH is known to be produced extrahepatically in certain
tissues, including the placenta (35). It is likely, that in the pla-
centae with staining of the stroma, the observed FH profile is a
heterogeneous combination of the maternal FH localized on the
syncytium and fetal FH localized in the villar arterial endothelium
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and tissue stromas. At these sites, FH would regulate the alternative
pathway.
C3 is the most central component of the C system. We found
C3 abundantly in the placenta. In the high-intensity area analy-
sis, C3b/iC3b deposition correlated with C1q and negatively with
FH deposition in the early-onset PE patients. This suggests that in
the most difficult cases of PE where, the alternative pathway has
become activated and, as a result, C3 deposits were observed, reg-
ulation by FH had failed to protect the placenta. This relationship
was missing in the late-onset PE and control groups. There were
no clear differences in the intensity or distribution of C3d between
placentas from PE patients and healthy controls. The kinetics of
C3d deposition differs from that of C3b and iC3b. C3d is usu-
ally found as a remnant from prolonged complement activation,
especially in basement membranes.
C3d was localized most clearly to the sub-syncytium basement
membrane. There was no difference in the intensity of C3d expres-
sion between the control and PE groups. This is in contrast to Sinha
et al., who observed that more C3d deposition occurred in the tro-
phoblast basement membrane in PE than in normal placentae, and
that the positivity was more marked in the severe PE group than
in patients with mild PE (36). In C3-knockout mice, C3 has been
found to be needed for successful pregnancy. C3-knockout mice
had a lower rate of conception and the fetal reabsorption rate was
higher, while the fetal and placental weights were lower in these
mice (8). Furthermore, in mice the C3-regulator Crry was found
to be crucial to a successful pregnancy (9).
While MCP is an important inhibitor of C activation in the
healthy maternal–fetal interface, C4bp apparently has a different
role in binding mainly to apoptotic structures and damaged STB.
This was reflected by a negative correlation between C4bp and
MCP intensity in the controls. The correlation between MCP and
DAF (CD55), which was observed in the high-intensity areas of the
control placentae showed that these regulators synergize each other
in the regulation of C activation in the third trimester placenta.
They are probably both needed for the control of C activation
on the syncytium. Membrane-bound regulators of complement
DAF, MCP, and CD59 have been observed in the healthy first
trimester and term placentae, where they serve to protect the devel-
oping placenta from C attack (5, 37, 38). In general, no differences
in the CD59 patterns or abundance were observed between the
preeclamptics and controls.
Increased endoglin staining was observed in PE samples. Our
results corroborate the findings of Sitras et al. and Nishizawa et al.
who both found increased levels of endoglin in PE, but could not
differentiate late- and early-onset patient groups with regard to
endoglin expression (39, 40). s-eng is a placenta-derived TGF-
beta co-receptor known to be elevated in PE although reports
of circulating s-eng levels correlating with disease severity are not
consistent (16). Since it is known that s-eng is more abundant in PE
than in healthy pregnancies,we used it as a positive control to verify
the ability of our methodology to detect changes in immunohis-
tochemical stain pattern and intensity between PE and control
placental samples.
CONCLUSION
Here, we have described for the first time the expression of a large
panel of C system components in the placentae of PE pregnancies.
It is apparent that complement is involved in multiple ways in both
normal pregnancy as well as in PE.
A notable difference between two soluble C regulators was
observed. C4bp was found to bind directly to apoptotic syncy-
tial structures while fetal FH apparently provides an overall, broad
scale protection to the placental tissue.
Correlation of MAC deposition with the classical pathway acti-
vating components in the patient groups and negative correlation
in the controls may be indicative of C regulation breakdown and/or
uncontrolled classical pathway activation in PE.
In our small cohort partial C4A deficiency was more frequent
in patients than controls. The high incidence of C4A deficiency
in PE might bear functional importance and the issue needs to be
examined in a larger material.
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